We measured concentrations of circulating MV types in patients with and without OSA via both single-labeling of MVs (annexin V+MVs, CD144+EMVs, CD41a+PMVs, and CD45+LMVs) and dual-labeling of MVs (annexin V+CD144+EMVs, annexin V+CD41a+PMVs, and annexin V+CD45+LMVs), and findings from these tests are shown in Table 3. This evidence concerns the gene PTPRC and obstructive sleep apnea syndrome.